Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Read More
Jun 11, 2026 | News, Regulatory
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Read MoreJun 10, 2026 | News, Regulatory
This new option for patients allows for as few as six maintenance injections per year
Read MoreTwo of Nuvalent’s NSCLC therapies have received FDA Breakthrough Therapy and Orphan Drug Designations
Read MoreJun 9, 2026 | News, Regulatory
Cases of measles have been rising in Europe since 2023
Read MoreThe companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Read MoreJun 5, 2026 | News, Regulatory
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
Read MoreThe deal will assist accelerate the discovery of RNAi therapeutics
Read MoreThe drug showed improvements in overall survival and progression-free survival in two cancers
Read MoreErleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Read MoreThe companies plan to research and develop 12 new cancer treatments
Read MoreJun 1, 2026 | News, Healthcare
The EU body underlines its commitment to diverse perspectives in medicines regulation
Read MoreOver 240 million people worldwide live with chronic hepatitis B
Read More
